抗忧郁症市场：按药物类别、给药途径、分销管道和地区划分

预计2024年全球抗忧郁症市场规模为187.2亿美元，预计2031年将达305亿美元，2024年至2031年年复合成长率(CAGR)为7.2%。

图：2024 年按地区分類的抗忧郁症市场占有率(%)

抗忧郁症是治疗重度忧郁症的药物。它用于改变大脑化学物质，以缓解悲伤、兴趣丧失、内疚感和自我价值感低下、睡眠障碍和食慾不振、疲劳和注意力不集中等症状。忧郁症和其他精神疾病的盛行率和认知不断提高，推动了全球对抗抗忧郁症的需求。此外，大型製药企业开拓新的先进治疗方法也正在推动市场成长。然而，替代治疗方法的可用性以及与抗忧郁症相关的副作用在一定程度上限制了市场的扩张。

市场动态：

影响全球抗忧郁症市场成长的市场驱动因素包括忧郁症和其他精神疾病盛行率的上升、对忧郁症诊断和管理的认识不断提高、新产品的推出以及医疗保健需求的增加，其中包括支出的增加。根据世界卫生组织估计，全球有超过 2.64 亿人患有忧郁症。根据失能寿命 (YLD) 来衡量，忧郁症也是导致残疾的主要原因。此外，抗忧郁症治疗忧郁症以外的疾病，如焦虑症、创伤后压力症候群（PTSD）、月经焦虑症（PMDD）和慢性疼痛的接受度不断提高，也是推动市场成长的动力。然而，心理治疗、电痉挛治疗和社会支持等替代治疗方法的可用性限制了全世界对抗抗忧郁症的完全依赖。此外，随着抗忧郁症的使用，许多人会出现轻微到严重的副作用，例如失眠、性功能障碍、体重变化、胃肠道紊乱和头痛，这限制了依从性和整体市场收益。新型抗忧郁症的高成本也阻碍了市场开拓，特别是在价格敏感的开发中国家。学名药开发为解决预算有限的消费者未满足的需求提供了机会。

本研究的主要特点

本报告对全球抗忧郁症市场进行了详细分析，并呈现了以2023年为基准年的预测期（2024-2031年）的市场规模和年均增长率。

它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球抗忧郁症药物市场的主要企业的概况。

本研究涵盖的主要企业包括辉瑞、礼来、阿斯特捷利康、葛兰素史克和诺华。

该报告的见解将使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球抗忧郁症市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过用于分析全球抗忧郁症市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球抗忧郁症市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球抗忧郁症市场，依药物类别，2019-2031

• 选择性血清素再回收抑制剂（SSRI）
• Fluoxetine
• 舍曲林
• 其他的
• 正肾上腺素再回收抑制剂(SNRI)
• 文拉法辛
• Duloxetine
• 其他的
• 三环抗忧郁药物（TCA）
• 阿米替林
• 丙咪嗪
• 其他的
• 单胺氧化酵素抑制剂 (MAOIs)
• 苯乙肼
• 反苯环丙明
• 其他的
• 非典型抗忧郁症
• 安非他酮
• 曲唑酮
• 其他的

第六章全球抗忧郁症市场，依给药途径，2019-2031

• 口服
• 皮下的
• 静脉
• 其他的

第七章全球抗忧郁症市场，依通路，2019-2031

• 医院药房
• 零售药房
• 网路药房

第八章全球抗忧郁症市场，按地区，2019-2031

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• 公司简介
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson &Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

第10章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十一章调查方法

• 参考
• 调查方法

The Global Antidepressant Market is estimated to be valued at USD 18.72 Bn in 2024 and is expected to reach USD 30.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

Figure. Antidepressant Market Share (%), By Region 2024

Antidepressants are medications prescribed to treat major depressive disorders. They are used to alter brain chemistry in order to relieve symptoms such as sadness, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, fatigue, and poor concentration. The increasing prevalence of depression and other mental health disorders along with growing awareness is fueling the demand for antidepressants globally. Moreover, development of new and advanced treatment options by major pharmaceutical companies is also boosting market growth. However, availability of alternative treatment methods and side-effects associated with antidepressant drugs restrict the market expansion to some extent.

Market Dynamics:

The drivers influencing growth of global antidepressant market include rising incidence of depression and other mental health conditions, growing awareness about depression diagnosis and management, new product launches, and increasing expenditure on healthcare. According to WHO, over 264 million people are estimated to suffer from depression worldwide. Depression is also the leading cause of disability as measured by Years Lived with Disability (YLDs). Furthermore, growing acceptance of antidepressants for conditions other than depression such as anxiety disorders, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and chronic pain is driving their market growth. However, availability of alternative treatment methods such as psychotherapy, electroconvulsive therapy, and social support is restricting complete reliance on antidepressants globally. Also, many individuals experience mild to serious side-effects such as insomnia, sexual dysfunction, weight changes, gastrointestinal issues, and headaches with antidepressant use, which limits their compliance and overall market revenue. High costs of new antidepressants also hinder the market growth, especially in price-sensitive developing nations. Development of generics offers opportunities to address the unmet needs of consumers with budget constraints.

Key features of the study:

This report provides in-depth analysis of the global antidepressant market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 s the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global antidepressant market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, AstraZeneca, GlaxoSmithKline, and Novartis

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global antidepressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antidepressant market

Detailed Segmentation-

• By Drug Class
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Fluoxetine
  • Sertraline
  • Others
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Venlafaxine
  • Duloxetine
  • Others
  • Tricyclic Antidepressants (TCAs)
  • Amitriptyline
  • Imipramine
  • Others
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Phenelzine
  • Tranylcypromine
  • Others
  • Atypical Antidepressants
  • Bupropion
  • Trazodone
  • Others
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca
  • AbbVie Inc.
  • Johnson & Johnson
  • Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Antidepressant Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Antidepressant Market, By Drug Class, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Fluoxetine
• Sertraline
• Others
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Venlafaxine
• Duloxetine
• Others
• Tricyclic Antidepressants (TCAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Amitriptyline
• Imipramine
• Others
• Monoamine Oxidase Inhibitors (MAOIs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Phenelzine
• Tranylcypromine
• Others
• Atypical Antidepressants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bupropion
• Trazodone
• Others

6. Global Antidepressant Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Antidepressant Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospitals Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Antidepressant Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Eli Lilly and Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
  • Johnson & Johnson
  • H. Lundbeck AS
  • Sanofi
  • Bristol-Myers Squibb
  • Alkermes Plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Indivior PLC
  • Aurobindo Pharma

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Research Methodology

• References
• Research Methodology
• About us and Sales Contact